MetaVia Broadens Global Patent Protection for Vanoglipel Until 2035 MetaVia Inc. enhances its patent portfolio for vanoglipel, supporting treatments for metabolic and liver diseases, effective through 2035. Explore their strategic advancements.

MetaVia Broadens Global Patent Protection for Vanoglipel Until 2035 #USA #Cambridge #MetaVia #GPR119 #Vanoglipel

MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025 MetaVia Inc. will present promising data on Vanoglipel (DA-1241), a novel GPR119 agonist, at the upcoming AASLD Liver Meeting 2025, detailing its hepatoprotective effects.

MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025 #United_States #Washington,_D.C. #MetaVia #GPR119 #Vanoglipel

MetaVia to Present Innovative DA-1241 Research at ADA's 85th Scientific Sessions MetaVia Inc. will present groundbreaking findings on DA-1241, a GPR119 agonist, at the upcoming ADA's 85th Scientific Sessions in Chicago.

MetaVia to Present Innovative DA-1241 Research at ADA's 85th Scientific Sessions #USA #Chicago #MetaVia #DA-1241 #GPR119

MetaVia Unveils Promising Data on DA-1241 at EASL Congress 2025 At EASL Congress 2025, MetaVia shares significant findings on its GPR119 agonist, DA-1241, showing liver protective and glucose regulating effects in MASH patients.

MetaVia Unveils Promising Data on DA-1241 at EASL Congress 2025 #United_States #Cambridge #MetaVia #DA-1241 #GPR119